Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2021; 20(04): 374-376
DOI: 10.4103/wjnm.wjnm_98_21
Case Report

Fluorodeoxyglucose positron emission tomography–computed tomography in a pregnant woman with carcinoma breast

Abhishek Mahato
Department of Nuclear Medicine and PET-CT, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India
,
Richa Joshi
1   Department of Nuclear Medicine and Surgical Oncology, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India
,
S Harish
1   Department of Nuclear Medicine and Surgical Oncology, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India
,
Dharmesh Paliwal
1   Department of Nuclear Medicine and Surgical Oncology, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

A 35-year-old female with a 15-week period of gestation was detected with locally advanced cancer of the left breast. She was suggested to undergo a medical termination of pregnancy (MTP) followed by invasive Oncological imaging - Contrast enhanced computed tomography (CECT) chest–abdomen–pelvis/fluorodeoxyglucose positron emission tomography-CT (FDG PET-CT) for staging the disease. However, to avoid the risk of iatrogenic novel coronavirus 2019 infection to the patient, on her request, the hospital admission was carried out after the oncological workup and thus PET-CT was conducted before the MTP. FDG PET-CT revealed FDG avid primary in the left breast along with extensive metastases to liver and skeletal lesions. The developing fetus also showed physiological FDG uptake. The patient has undergone an MTP and is presently under treatment for metastatic breast cancer. The case report illustrates the radiation safety guidelines on fetal radiation exposure, steps to decrease fetal radiation exposure, and illustration of fetal FDG uptake.

Keywords

Breast cancer - fetal fluorodeoxyglucose - pregnancy

Financial support and sponsorship

Nil.




Publication History

Received: 17 August 2021

Accepted: 29 August 2021

Article published online:
24 March 2022

© 2021. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gill MM, Sia W, Hoskinson M, Niven E, Khurana R. The use of PET/CT in pregnancy: A case report of malignant parathyroid carcinoma and a review of the literature. Obstet Med 2018;11:45-9.
  • 2 American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee opinion no. 656: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2016;127:e75-80.
  • 3 The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 2007;37:1-332.
  • 4 ICRP publication 105. Radiation protection in medicine. Ann ICRP 2007;37:1-63.
  • 5 Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR. J Nucl Med 2015;56:1218-22.
  • 6 Stabin MG. Proposed addendum to previously published fetal dose estimate tables for 18F-FDG. J Nucl Med 2004;45:634-5.
  • 7 Hsieh TC, Wu YC, Sun SS, Chu LY, Yen KY, Kao CH. FDG PET/CT of a late-term pregnant woman with breast cancer. Clin Nucl Med 2012;37:489-91.
  • 8 Calais J, Hapdey S, Tilly H, Vera P, Chastan M. Hodgkin's disease staging by FDG PET/CT in a pregnant woman. Nucl Med Mol Imaging 2014;48:244-6.